Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$1.81 USD
-0.13 (-6.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRCA 1.81 -0.13(-6.70%)
Will VRCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Other News for VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Wall Street Breakfast: The Week Ahead
Catalyst Watch: August Jobs Report, Intel event, Broadcom earnings, and Costco sales
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Verrica Pharmaceuticals CCO Joe Bonaccorso Resigns, Assumes Consulting Role